AKT1 is emerging as a useful target for treating cancer. Herein, we discovered a new set of ligands that inhibit the AKT1, as shown by in vitro binding and cell line studies, using a newly designed virtual screening protocol that combines structurebased pharmacophore and docking screens. Taking together with the biological data, the combination of structure based pharamcophore and docking methods demonstrated reasonable success rate in identifying new inhibitors (60-70%) proving the success of aforementioned approach. A detail analysis of the ligand-protein interactions was performed explaining observed activities.
Introduction
AKT, also known as protein kinase B (PKB), is a serine/threonine kinase that exists in three homologous human isoforms (AKT1, AKT2 and AKT3). AKT isozymes play significant roles in apoptotic pathways and signal transduction, and therefore, influence cellular survival and proliferation.
1-3 AKT over-expression exerts considerable anti-apoptotic effects in many cell types. [1] [2] [3] Many cancers (e.g., breast, ovarian, prostate carcinomas and glioblastomas) were found to involve mutation or loss of the AKT negative regulator PTEN. 1,2 Accordingly, inhibiting AKT signaling is a promising approach toward managing many cancers. [4] [5] [6] [7] Several in silico virtual screenings (VS) have been already used, followed by in vitro experiments, to discover new classes of AKT1 inhibitors. For instance, Dong et al. 8 combined ligand-based pharmacophore and docking studies to identify nine promising hits. Biological testing of six of these leads indicated inhibition, and IC 50 values between 3.9 and 143.9 µM. Cell line tests on two of these ligands indicated apoptosis. Alternatively, Chuang et al. 9 employed solely structure-based docking. From 48 promising candidates, 12 compounds displayed comparable or more potent cytotoxic activity compared to the reference compound, H-89, against
HCT-116 colon cancer cells. The best results came from compounds a46 and a48: IC 50 values of 201 and 158 µM, respectively. Compound a48 showed 75% inhibition at 100 µM concentration. Al-Sha're et al. 10 used pharmacophore/quantitative structure-activity relationship (QSAR) modeling to identify optimal binding models and found new dual AKT3/AKT1
inhibitors. All 40 tested hits fit a pharmacophore model. Unfortunately, only six of them exhibited anti-AKT3 and/or AKT1 bioactivities.
Thus, as previously suggested, 11 combining ligand-based pharamcophore and docking studies results in more success than either approach alone. Researchers have applied similar methods to search for new AKT2 and AKT3 inhibitors. 10,12 Herein, we have identified and characterized new AKT1 inhibitors. We used a VS protocol that combines structure-based pharmacophore and docking screens, and we tested our results against biochemical assays.
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Methods
Virtual Screening
A combination of structure-and ligand-based approaches provides superior results for drug discovery in silico, relative to using either approach alone. 11 However, for many targets there are no (or limited) ligands available, thus rendering this combination impossible. In these cases, structure-based pharmacophore models could be of great help and should be intensively tested.
Herein, we tested whether a recently introduced structure-based pharmacophore approach in Phase software (Schrödinger package), in combination with docking followed by rescoring with the new Glide-SP scoring function, can achieve reasonable virtual screening (VS) results.
We tested this approach on the full (102 targets) DUD-E benchmark. Surprisingly, we found that the structure-based pharmacophore hypothesis (an evaluation of the docking of more than 600 small fragments; the default number in Phase) performs well for most of the targets, with an average active ligand recovery rate of 10%-15% during the first 1% database screen.
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The MD-prepared structures further increased these values. These results are equivalent to the ligand-based pharmacophore VS. The docking technique performed much better on the DUD-E set. Early enrichment performance shows on average of approximately 30% of known activities are recovered in screening the top-ranked 1% of recovered decoys, similarly to the previous DUD test results. Furthermore, we confirmed an improvement of the Glide-SP scoring function, as claimed on Schrödinger website, as it is shown on the ACE test target, which usually produced unsatisfied results in previous reports ( Figure S14 in Fratev et.
al. 14 ).
However, the primary aim of a real drug discovery project is very early enrichment performance; i.e., how many active compounds will be discovered in the top 10 to 50 ligands, which we term the success rate (SR) or efficiency (EF). According to our data, combining these methods achieves an impressive result: a nearly 75% success rate for all 102 targets, often reaching 100%, for the top 10 ligands. 13 Based on our data, we developed a new VS protocol using the top 10% of the pharmacophore search (3.5 million ZINC compounds in our case) as an input to the docking and scoring by Glide-SP (35,000 ligands). We performed all calculations using Schrödinger's Phase and Glide software packages, as implemented in Schrödinger 2017-4 suite. 15 Our approach may advance drug discovery, and we have already applied it toward the discovery of GlyT2 transporter inhibitors.
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Structure and ligand preparation
We used the structure of AKT1 in complex with an inhibitor (PDB ID: 3QKK) as the basis for our in silico studies. We undertook X-ray structure preparation for subsequent modeling with Protein Preparation Wizard. We added missing atoms and the hydrogen bonding network by assigning tautomer/ionization states, sampling water orientations, and flipping Asn, Gln, and His residues in the plane of their π-systems. All resolved crystal water molecules were deleted. Ligand 3D structures were loaded as SDF files from the ZINC library.
Pharmacophore and docking
As aforementioned, we used a combination of structure-based pharmacophore and docking approaches as implemented in Schrödinger Suite 2017-4. We employed the default setting for both of these methods. An exception was that during the docking we kept 10,000 (instead of 5,000) initial docking poses, and we employed the rewards of hydrogen bonds as an option.
In vitro binding assays 
Cytotoxicity assay
To evaluate the cytotoxic activity of the compounds presented in this study, the previously validated Differential Nuclear Staining (DNS) assay was used. 
Results and discussion
In silico Virtual screening
Toward discovering new AKT1 inhibitors, we developed a special protocol for our highthroughput virtual screening (HTVS). We combined a recently introduced structure-based pharmacophore approach with the docking method in the framework of the Schrödinger 2017-4 package. [13] [14] [15] This type of pharmacophore model is based on the docking of several hundred fragments into the binding site (specifically, the AKT1 ATP binding pocket). The pharmacophore points are defined in accordance with their best position . These are the places within the binding site that were predicted to be essential for ligand binding (Figure 1 A). Eight point pharmacophore model was created for our VS study (Figure 1 B) . This model requested a presence of an aromatic ring with both acceptor and donor capable substituents at the upper part of the ATP binding site, aromatic and/or hydrophobic core, along with a donor, at the center and also an aromatic rings that would be able to interact with the loop residues at the lower end of the binding pocket. We used the default settings (albeit four matched pharmacophore points, not all eight), to test the success of the structurebased pharmacophore approach when information on ligand-protein interactions is limited.
However, this could be further refined based on more AKT1's specific key structural features.
Initital screening was done on 3.5 million compounds from the ZINC15 18 library via the 7 developed pharmacophore model. Further, the top 35,000 best candidates were subjected to docking, using the Gide SP scoring function, and finally top-scoring 100 ligands were visually inspected and nine promising candidates with scores of at least approximately −9kcal/mol were chosen for biological evaluation.
We initially developed and tested our approach on the DUD-E dataset. 13 The DUD-E results for AKT1 (Figure 2 ) gave a recovery (success) rate of the active ligands, versus decoys, of 100%, 90%, and 76% for the top 10, 20, and 50 ligands, respectively. Furter,
We successfully applied our protocol during HTVS for identifying new glycine 2 transporter inhibitors(GlyT2), and discovered several hits with submicromolar activity. The best hit had an IC 50 value of 0.48 µM against human GlyT2 protein.
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In vitro binding assay and Cytotoxicity in human cancer cell lines
The potential anticancer activity of the proposed molecules were evaluated for 1)their AKT1 binding affinity using in vitro binding assays and 2)cytotoxicity using human cell line experiments. Initially, the selected nine compounds ( Figure 3 shows the structures, ZINC number, and docking score of the slected compounds)were tested with in vitro single-point AKT1 binding assay at 10 µM concentration and also cell line experiments were performed for them in the acute lymphoblastic leukemia cell line; CEM by a differential nuclear staining assay. The cell line assay consists on performing live cell imaging of a treated population to determine cell viability. Cells were exposed for 48 h to a gradient of concentrations of the compounds ranging from 0.1 to 7.5 M. Thereafter, images were acquired and analyzed to obtain percentages of live and dead cells(See Methods section).
Five of these ligands(compounds 1, 2, 5, 6, and 13) showed an AKT1 inhibition of more than 10% at 10µM; further testing was done at 100 µM concentration ( Table 1) . As shown in figure 4A , the CEM cells exhibited differential amounts of cytotoxicity against the different compounds tested. Figure 4A ). Those four compounds were selected to construct the dose-response curves ( Figure 4B ). Also, compound 5 and 6 maintained the uppermost values throughout the range of experimental concentrations ( Figure 4B ). Interestingly, compound 6 was found to be one of the strongest AKT inhibitors tested in this study (Table 1) , presenting 45% of inhibition at a 100 µM. Another example is compound z18, which showed weak AKT1 activity yet produced significant tumor cell apoptosis (nearly 40% at 50 µM concentration). The literature predicts this compound to also be a GPR91 (succinate receptor 1) inhibitor, which is pertinent to the PI3K/Akt/mTOR pathway via upregulation of VEGF 20 . 21 Thus, one can expect this compound to exhibit a synergetic effect, in that it can bind to other proteins in the AKT signaling cascade. We are currently testing this hypothesis in our laboratory.
Thus, finding selective ligands via VS is challenging, necessitating a combination of cell line and binding experiments. Binding tests of a panel with many more kinases will also be helpful. Additional selectivity and activity improvements can be achieved relatively easily by more advanced in silico methods, such as free energy perturbation (FEP) and especially Interestingly, the IC 50 values of new hits in most of VS studies were at greater than 50-100 µM. One of the reasons is that we omitted the presence of natural peptide. Furthermore, our pharmacophore model was the default model; i.e., we did not improve it based on specific AKT1 structural features or expert opinion. For instance, the aromatic points R42 and R43 (Figure 1 B) could be deleted, the number of pharmacophores could be reduced only to the most significant, and most importantly the requested number of matches could be set more strictly and increased. However, one of our aims in this study was to evaluate also the default performance of the method as it is implemented in Schrödinder package and requested 4 of 10 the best approach and we highly recommend it.
14 Structural basis of the observed activity
The compound 6 structure is typical for an AKT inhibitor. It has a purine core attached to piperazine. However, the indazole ring may be too big to fit well and interact with the P-loop, in particular Phe161 ( Figure 6 ). Compound 2 has similar structural features and almost identical interactions at the upper part of the ATP binding pocket (Glu228 and Ala230). It also forms hydrogen bonds with Glu234 and Glu278, but does not contact the loop and exhibits only moderate activity, proving that interactions with the loop residues are an important factor for binding ( Figure 7 ). This has been demonstrated in structure activity optimization studies, 25 and is also evident from data of compound 4. The last ligand provides neither stable contact with the loop residues nor with those from the other side of the binding grove, and the activity was completely lost. This also provides additional information for further SAR studies. Thus, appropriate optimization, guided by approaches such as FEP+, may greatly enhance the activity. On the other hand, the ring of the most active ligand, compound 1, exhibits interactions along the ATP binding pocket and forms several hydrogen bonds within the loop (residues Phe161 and Gly162), which contributes to its activity (Figure 8 ).
Conclusions
Our data demonstrates that a combination of structure-based pharmacophore and docking approaches was successful in discovering new potential AKT1 inhibitors. When we combined the binding and cell line data, we obtained a reasonable success rate of identifying new hits (60%-70%). However, during the pharmacophore search the choice of a model matching more features, e.g. more specific and significant potential ligand-protein interactions, seems to be critical for both activity and selectivity in identifying new hits. Recently, we identified also highly potent (≤0.5 µM) glycine transporter 2 leads in this manner. 14 Thus, our approach is useful for VS when (1) no ligands are known for a target, (2) the number of ligands is limited, or (3) a conventional ligand-based pharmacophore search is infeasible. 
